| Literature DB >> 29401570 |
Myungguen Chung1, Soo Young Cho2, Young Seek Lee1.
Abstract
We aimed to understand the molecular changes in host cells that accompany infection by the seasonal influenza A H1N1 virus because the initial response rapidly changes owing to the fact that the virus has a robust initial propagation phase. Human epithelial alveolar A549 cells were infected and total RNA was extracted at 30 min, 1 h, 2 h, 4 h, 8 h, 24 h, and 48 h post infection (h.p.i.). The differentially expressed host genes were clustered into two distinct sets of genes as the infection progressed over time. The patterns of expression were significantly different at the early stages of infection. One of the responses showed roles similar to those associated with the enrichment gene sets to known 'gp120 pathway in HIV.' This gene set contains genes known to play roles in preventing the progress of apoptosis, which infected cells undergo as a response to viral infection. The other gene set showed enrichment of 'Drug Metabolism Enzymes (DMEs).' The identification of two distinct gene sets indicates that the virus regulates the cell's mechanisms to create a favorable environment for its stable replication and protection of gene metabolites within 8 h.Entities:
Keywords: A549 Cells; Apoptosis; Gene expression regulation; High-throughput nucleotide sequencing; Influenza A virus H1N1 subtype; Sequence analysis RNA
Year: 2018 PMID: 29401570 PMCID: PMC5933896 DOI: 10.4062/biomolther.2017.240
Source DB: PubMed Journal: Biomol Ther (Seoul) ISSN: 1976-9148 Impact factor: 4.634
Fig. 1.Unsupervised hierarchical clustering of gene set variation analysis. Gene set variation analysis (GSVA) is a non-parametric, unsupervised method for estimating variation of gene set enrichment through the expression data of infected cell. GSVA transformed each line gene-based expression matrix of gene by sample to matrix of a gene-set by sample. The matrix shows clear separation between the groups.
Fig. 2.Visualization of differential expression gene sets (DEGs) in the two groups. (A) early stage expression from 30 min to 8 h and (B) the late stage expression pattern, which progressively increased after 8 h of infection. (C) A network graph showing correlated genes. The graph shows clear separation between the groups.
Time series DEGs: GO annotation and pathway menrichment analysis for all timepoints and early- and late-specific timepoints
| Gene groups | Category | Term | Count | % | Fold enrichment | Bonferroni | Benjamini | FDR | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Early stage changed gene sets (<8 hour) | HIV_Interaction | env | env:Envelope surface glycoprotein gp120 | 20 | 5.68 | 0.007 | 1.65 | 0.05 | 0.05 | 3.54 |
| Molecular function | GO:0015267 | Channel activity | 28 | 5.53 | 2.24E-05 | 2.49 | 0.01 | 0.01 | 0.03 | |
| GO:0022803 | Passive transmembrane transporter activity | 28 | 5.53 | 2.34E-05 | 2.49 | 0.01 | 0.01 | 0.03 | ||
| GO:0030955 | Potassium ion binding | 14 | 2.77 | 4.50E-05 | 4.01 | 0.03 | 0.01 | 0.07 | ||
| GO:0022838 | Substrate specific channel activity | 26 | 5.14 | 9.05E-05 | 2.40 | 0.05 | 0.01 | 0.13 | ||
| KEGG Pathway | hsa04080 | Neuroactive ligand-receptor interaction | 19 | 3.75 | 1.97E-04 | 2.68 | 0.02 | 0.02 | 0.23 | |
| hsa00980 | Metabolism of xenobiotics by cytochrome 450 | 9 | 1.78 | 2.06E-04 | 5.41 | 0.02 | 0.01 | 0.24 | ||
| hsa00982 | Drug metabolism | 9 | 1.78 | 2.60E-04 | 5.24 | 0.03 | 0.01 | 0.30 |
Category refers to the GO functional category; Count refers to the number of enrichment DEGs.
Fig. 3.The reconstruction signaling and regulatory network of gp120 at apoptosis pathway at the early stage. Schema of the gp120 protein regulated pathway in influenza-infected cells. The genes highlighted in blue are the genes related to “glycoprotein gp120” from the enrichment gene analysis. The remaining genes were identified through network analysis (PATHWAY studio).
Drug-gene interaction database for candidate genes
| Gene | Drug | CFB | CFCT | DB | GPI | PG | TALC | TE | TT | TC | #of DB | # of PMID | Sum score (DB+PMID) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCL2 | PACLITAXEL | - | TRUE | TRUE | - | - | - | TRUE | - | TRUE | 4 | 5 | 9 |
| BCL2 | DOCETAXEL | - | - | TRUE | - | - | - | - | - | TRUE | 2 | 6 | 8 |
| BCL2 | RASAGILINE | - | - | TRUE | - | - | - | - | - | - | 1 | 5 | 6 |
| BCL2 | OBLIMERSEN | - | - | - | - | - | TRUE | - | TRUE | TRUE | 3 | 0 | 3 |
| FPR1 | NEDOCROMIL | - | - | TRUE | - | - | - | - | - | - | 1 | 3 | 4 |
| NR1H4 | CHENODEOXYCHOLIC ACID | - | - | TRUE | TRUE | - | - | - | - | - | 2 | 2 | 4 |
| NR1H4 | FEXARAMINE | - | - | TRUE | TRUE | - | - | - | - | - | 2 | 2 | 4 |
| TERT | GV1001 | - | - | TRUE | - | - | - | - | - | TRUE | 2 | 1 | 3 |
| TNF | THALIDOMIDE | - | - | TRUE | - | - | - | TRUE | TRUE | TRUE | 4 | 7 | 11 |
| TNF | AMRINONE | - | - | TRUE | - | - | - | - | - | - | 1 | 5 | 6 |
| TNF | CHLOROQUINE | - | - | TRUE | - | - | - | - | - | - | 1 | 5 | 6 |
| TNF | CLENBUTEROL | - | - | TRUE | - | - | - | - | - | - | 1 | 5 | 6 |
| TNF | PSEUDOEPHEDRINE | - | - | TRUE | - | - | - | - | - | - | 1 | 2 | 3 |
CFB: Clearity Foundation Biomarkers, CFCT: Clearity Foundation Clinical Trial, DB: Drugbank, GPI: Guide to Pharmacology Interactions Version: 04-March-2015, PG: PharmGKB - The Pharmacogenomics Knowledgebase, TALC: Targeted Agents in Lung Cancer, TE: Trends in the exploitation of novel drug targets, TT: Therapeutic Target Database, Version 4.3.02, TC: The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication.